Marcy l'Etoile, France - January 19, 2011. At constant exchange rates and scope of consolidation:
- Sales growth: 4.9%
- Excluding the H1N1 impact, sales growth: 6.4% vs. 6.2% in 2009
- Rapid rise in “Emerging 7” sales: + 27%, excluding the H1N1 impact
- Strong growth drivers
- Clinical microbiology: + 7.6%
- VIDAS®: + 9.2%
- Industrial applications: + 8.1%
- Robust instrument sales: + 19.5%
BioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2010.
To access the audio replay dial
- France: +33 (0)1 74 20 28 00
- Europe: +44 (0)20 7111 1244
- USA: +1 347 366 9565
Access code: 4310468#
Replay available until February 2, 2011
Download
- Filename
- pr_biomerieux_q4_sales_2010_en2.pdf
- Size
- 70 KB
- Format
- application/pdf